303 related articles for article (PubMed ID: 36383189)
1. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
van Bommel MHD; IntHout J; Veldmate G; Kets CM; de Hullu JA; van Altena AM; Harmsen MG
Hum Reprod Update; 2023 Mar; 29(2):197-217. PubMed ID: 36383189
[TBL] [Abstract][Full Text] [Related]
2. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
Schrijver LH; Antoniou AC; Olsson H; Mooij TM; Roos-Blom MJ; Azarang L; Adlard J; Ahmed M; Barrowdale D; Davidson R; Donaldson A; Eeles R; Evans DG; Frost D; Henderson A; Izatt L; Ong KR; Bonadona V; Coupier I; Faivre L; Fricker JP; Gesta P; van Engelen K; Jager A; Menko FH; Mourits MJE; Singer CF; Tan YY; Foretova L; Navratilova M; Schmutzler RK; Ellberg C; Gerdes AM; Caldes T; Simard J; Olah E; Jakubowska A; Rantala J; Osorio A; Hopper JL; Phillips KA; Milne RL; Beth Terry M; Noguès C; Engel C; Kast K; Goldgar DE; van Leeuwen FE; Easton DF; Andrieu N; Rookus MA;
Am J Obstet Gynecol; 2021 Jul; 225(1):51.e1-51.e17. PubMed ID: 33493488
[TBL] [Abstract][Full Text] [Related]
5. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.
Park J; Huang D; Chang YJ; Lim MC; Myung SK
Carcinogenesis; 2022 Apr; 43(3):231-242. PubMed ID: 34958358
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
Moorman PG; Havrilesky LJ; Gierisch JM; Coeytaux RR; Lowery WJ; Peragallo Urrutia R; Dinan M; McBroom AJ; Hasselblad V; Sanders GD; Myers ER
J Clin Oncol; 2013 Nov; 31(33):4188-98. PubMed ID: 24145348
[TBL] [Abstract][Full Text] [Related]
7. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
Narod SA; Sun P; Ghadirian P; Lynch H; Isaacs C; Garber J; Weber B; Karlan B; Fishman D; Rosen B; Tung N; Neuhausen SL
Lancet; 2001 May; 357(9267):1467-70. PubMed ID: 11377596
[TBL] [Abstract][Full Text] [Related]
8. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.
Friebel TM; Domchek SM; Rebbeck TR
J Natl Cancer Inst; 2014 Jun; 106(6):dju091. PubMed ID: 24824314
[TBL] [Abstract][Full Text] [Related]
9. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
10. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of
Stroot IAS; Brouwer J; Bart J; Hollema H; Stommel-Jenner DJ; Wagner MM; van Doorn HC; de Hullu JA; Gaarenstroom KN; Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez Garcia EB; Ausems MGEM; Boere IA; van Engelen K; van Asperen CJ; Schmidt MK; Wevers MR; de Bock GH; Mourits MJE;
J Clin Oncol; 2023 May; 41(14):2523-2535. PubMed ID: 36809028
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Narod SA; Dubé MP; Klijn J; Lubinski J; Lynch HT; Ghadirian P; Provencher D; Heimdal K; Moller P; Robson M; Offit K; Isaacs C; Weber B; Friedman E; Gershoni-Baruch R; Rennert G; Pasini B; Wagner T; Daly M; Garber JE; Neuhausen SL; Ainsworth P; Olsson H; Evans G; Osborne M; Couch F; Foulkes WD; Warner E; Kim-Sing C; Olopade O; Tung N; Saal HM; Weitzel J; Merajver S; Gauthier-Villars M; Jernstrom H; Sun P; Brunet JS
J Natl Cancer Inst; 2002 Dec; 94(23):1773-9. PubMed ID: 12464649
[TBL] [Abstract][Full Text] [Related]
12. Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors.
van Bommel MHD; Steenbeek MP; IntHout J; Hermens RPMG; Hoogerbrugge N; Harmsen MG; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JM; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Prins JB; Custers JAE; de Hullu JA
Support Care Cancer; 2022 Apr; 30(4):3409-3418. PubMed ID: 34997316
[TBL] [Abstract][Full Text] [Related]
13. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
Wang Y; Song Z; Zhang S; Wang X; Li P
Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860
[TBL] [Abstract][Full Text] [Related]
14. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
Schrijver LH; Mooij TM; Pijpe A; Sonke GS; Mourits MJE; Andrieu N; Antoniou AC; Easton DF; Engel C; Goldgar D; John EM; Kast K; Milne RL; Olsson H; Phillips KA; Terry MB; Hopper JL; van Leeuwen FE; Rookus MA
J Natl Cancer Inst; 2022 Apr; 114(4):540-552. PubMed ID: 35048954
[TBL] [Abstract][Full Text] [Related]
15. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Xia YY; Gronwald J; Karlan B; Lubinski J; McCuaig JM; Brooks J; Moller P; Eisen A; Sun S; Senter L; Bordeleau L; Neuhausen SL; Singer CF; Tung N; Foulkes WD; Sun P; Narod SA; Kotsopoulos J;
Gynecol Oncol; 2022 Mar; 164(3):514-521. PubMed ID: 35063280
[TBL] [Abstract][Full Text] [Related]
16. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
Borde J; Laitman Y; Blümcke B; Niederacher D; Weber-Lassalle K; Sutter C; Rump A; Arnold N; Wang-Gohrke S; Horváth J; Gehrig A; Schmidt G; Dutrannoy V; Ramser J; Hentschel J; Meindl A; Schroeder C; Wappenschmidt B; Engel C; Kuchenbaecker K; Schmutzler RK; Friedman E; Hahnen E; Ernst C
BMC Cancer; 2022 Jun; 22(1):706. PubMed ID: 35761208
[TBL] [Abstract][Full Text] [Related]
17. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.
Huber D; Seitz S; Kast K; Emons G; Ortmann O
Arch Gynecol Obstet; 2020 Apr; 301(4):875-884. PubMed ID: 32140806
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
Jernström H; Sandberg T; Bågeman E; Borg A; Olsson H
Int J Gynecol Cancer; 2006; 16 Suppl 2():497. PubMed ID: 17010055
[TBL] [Abstract][Full Text] [Related]
19. The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
Eoh KJ; Park EY; Chang YJ; Ha HI; Hong J; Huang D; Nam EJ; Lim MC
Gynecol Oncol; 2021 Oct; 163(1):142-147. PubMed ID: 34304906
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]